Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The drug ...

Novartis (NYSE:NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH. The study ...

Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway. APPULSE-PNH is a phase IIIB multicenter, single-arm, open-label study to evaluate the efficacy and safety of twice ...

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for rare disease paroxysmal ...

Iptacopan, an oral factor B inhibitor, is currently approved under the brand name Fabhalta for the treatment of adults with PNH. Topline results were announced from a phase 3b study evaluating the ...

Novartis announced positive topline results from APPULSE-PNH, a phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta (iptacopan) in adult patients with ...

today announced it will expand its collaboration with Novartis to include Fabhalta® (iptacopan), providing access to innovative treatment in low resource countries for PNH, a rare and ...

The Scottish Medicines Consortium (SMC) approved the drugs for use by NHS Scotland.

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved ...

Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is an oral, Factor B ...

Novartis NVS announced positive top-line results from a late-stage study on Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is an oral, Factor B ...